1. Figure 1 Proposed risk stratification for patients with NAFLD
Figure 1 | Proposed risk stratification for patients with NAFLD. After suspected NAFLD has been confirmed, patients can be stratified by their risk of NAFLD progression, on the basis of their noninvasive risk factor profiles. If noninvasive risk factors cannot definitively determine risk profile, liver biopsy can be used to aid stratification. Presence of MELD >10 or HVPG >10 mmHg is associated with development of adverse clinical outcomes within 1–2 years in 20% of patients. *High-quality data for the use of Fibroscan® (Echosens, France) in patients with NASH are emerging and require confirmation. ‡Cut-off values reported by Angulo et al.118. ALT, alanine aminotransferase; APRI, aspartate aminotransferase to platelet ratio index; FIB-4, fibrosis-4 index; HVPG, hepatic venous pressure gradient; MELD, model for end-stage liver disease; NFS, NAFLD fibrosis score; T2DM, type 2 diabetes mellitus.
Rinella, M. E. & Sanyal, A. J. (2016) Management of NAFLD: a stage-based approach
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro